Diagnostics (Aug 2023)

Perilesional Targeted Biopsy Combined with MRI-TRUS Image Fusion-Guided Targeted Prostate Biopsy: An Analysis According to PI-RADS Scores

  • Masayuki Tomioka,
  • Kensaku Seike,
  • Hiromi Uno,
  • Nami Asano,
  • Haruo Watanabe,
  • Risa Tomioka-Inagawa,
  • Makoto Kawase,
  • Daiki Kato,
  • Manabu Takai,
  • Koji Iinuma,
  • Yuki Tobisawa,
  • Keita Nakane,
  • Kunihiro Tsuchiya,
  • Takayasu Ito,
  • Takuya Koie

DOI
https://doi.org/10.3390/diagnostics13152608
Journal volume & issue
Vol. 13, no. 15
p. 2608

Abstract

Read online

A prostate-targeted biopsy (TB) core is usually collected from a site where magnetic resonance imaging (MRI) indicates possible cancer. However, the extent of the lesion is difficult to accurately predict using MRI or TB alone. Therefore, we performed several biopsies around the TB site (perilesional [p] TB) and analyzed the association between the positive cores obtained using TB and pTB and the Prostate Imaging Reporting and Data System (PI-RADS) scores. This retrospective study included patients who underwent prostate biopsies. The extent of pTB was defined as the area within 10 mm of a TB site. A total of 162 eligible patients were enrolled. Prostate cancer (PCa) was diagnosed in 75.2% of patients undergoing TB, with a positivity rate of 50.7% for a PI-RADS score of 3, 95.8% for a PI-RADS score of 4, and 100% for a PI-RADS score of 5. Patients diagnosed with PCa according to both TB and pTB had significantly higher positivity rates for PI-RADS scores of 4 and 5 than for a PI-RADS score of 3 (p p = 0.0009, respectively). Additional pTB may be performed in patients with PI-RADS ≥ 4 regions of interest for assessing PCa malignancy.

Keywords